Page 230 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Chapter 8
Overall risk of bias
Outcome measurement
(n=33) (n=127) (n=497) (n=125) (n=188) (n=61) (n=539) (n=122) 12345678 Bologna GSTT15 HOVON84 IAEA NCRI Nordic US PETAL SAKK
50 (41) 33 (27) 28 (23) 6 (4.9) 5 (4.1)
214 (39.7) 126 (23.4) 17 (3.2) 21 (3.9) 74 (13.7) 87 (16.1)
12 (19.7) 26 (42.6) 12 (19.7) 6 (9.8) 5 (8.2)
13 (6.9) 56 (29.8) 46 (24.5) 39 (20.7) 34 (18.1)
24 (19.2) 34 (27.2) 25 (20) 35 (28) 7 (5.6)
107 (21.5) 110 (22.1) 174 (35) 24 (4.8) 82 (16.5)
12 (12.1) 43 (40.2) 28 (26.2) 12 (11.2) 31 (29)
6 (18.2) 22 (66.7) 4 (12.1) 1 (3)
107 (87.7) 14 (11.5) 1 (0.8)
470 (87.2) 68 (12.6) 1 (0.2)
21 (34.4) 15 (24.6) 25 (41)
167 (88.8) 20 (10.6) 1 (0.5)
110 (88) 15 (12)
324 (65.2) 135 (27.2) 38 (7.6)
107 (84.3) 20 (15.7)
7 (21.2) 26 (78.8)
rituximab intensification, ∆SUVmax: reduction in
Abbreviations: I-PET: interim PET, IPI: International Prognostic Index, R: rituximab, RR-CHOP14: R-CHOP with Standardized Uptake Value.
Low Low Low Low Low Low Low Low
Study attrition
Study participation
Supplemental Table 1. Continued
Total (n=1692)
1 378 (22.3)
2 315 (18.6)
3 386 (22.8)
4 496 (29.3)
5 100 (5.9)
≥66/70% 1336 (79.0) <66/70% 197 (11.6) missing 159 (9.4) Deauville score (%)
Missing 17 (1.0) ∆SUVmax (%)
Prognostic factor measurement Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low Low ‘Quality Assessment in Prognostic Studies’ (QUIPS) tool. of bias assessment using the
Moderate Low
Low Low
Low Low
Low Low
Low Low
Low Low
Low Low
Low Low
Supplemental Table 2. Risk
HOVON84
Bologna
GSTT15
NordicUS
PETAL
IAEA
NCRI
SAKK
228